Biosimilars for the next decade in Latin America: a window of opportunity

References

• Huang Y, Su D, Kim Y. Timing choice and catch-up strategy for latecomers in emerging green technologies: An exploration study on China’s high-speed rail industry. J Clean Prod. 2020;276:124257. doi: 10.1016/j.jclepro.2020.124257
   Web of Science ®Google Scholar
• Dolgin E. Startups set off new wave of mRNA therapeutics after the vaccine triumphs of Pfizer/BioNTech and Moderna Inc., a raft of startups is developing mRNA, circular RNA and self-amplifying RNA therapeutics. Nature Biotechnol. 2021;39(9):1029–1031. doi: 10.1038/s41587-021-01056-6
   PubMedGoogle Scholar
• Do H, Budhwar P, Shipton H, et al. Building organizational resilience, innovation through resource-based management initiatives, organizational learning and environmental dynamism. J Bus Res. 2022;141:808–821. doi: 10.1016/j.jbusres.2021.11.090
   Web of Science ®Google Scholar
• Calina D, Docea AO, Petrakis D, et al. Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review). Int J Mol Med. 2020;46(1):3–16. doi: 10.3892/ijmm.2020.4596
   PubMed Web of Science ®Google Scholar
• Rennane S, Baker L, Mulcahy A. Estimating the cost of industry investment in drug research and development: a review of methods and results. J Health Care Organ, Provision, And Financing. 2021;58:1–11. doi: 10.1177/00469580211059731
   Web of Science ®Google Scholar
• Kovac M, Datta S, Spruk R. Pharmaceutical product liability, litigation regimes, and the propensity to patent: an empirical firm-level investigation. SAGE Open April-June; 2021 p. 1–18. doi: 10.1177/21582440211009470
   Google Scholar
• DiMasi J, Grabowski H, Hansen R. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016;47:20–33.
   PubMed Web of Science ®Google Scholar
• Schlander M, Hernandez‑Villafuerte K, Cheng C-Y. How much does it cost to research and develop a new drug? A systematic review and assessment. PharmacoEconomics. 2021;39(11):1243–1269. doi: 10.1007/s40273-021-01065-y
   PubMed Web of Science ®Google Scholar
• Rao K, Gowthami B, Naveen R, et al. An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19. Current Res Pharmacol Drug Discov. 2021;2:100063. doi: 10.1016/j.crphar.2021.100063
   PubMedGoogle Scholar
• Lurie N, Saville M, Hatchett R, et al. Developing COVID-19 vaccines at pandemic speed. N Engl J Med. 2020;382(21):1969–1973. doi: 10.1056/NEJMp2005630
   PubMed Web of Science ®Google Scholar
• Kim J, Hotez P, Batista C. Operation Warp Speed: implications for global vaccine security. Lancet Glob Health. 2021;9(7):e1017–21. doi: 10.1016/S2214-109X(21)00140-6
   PubMed Web of Science ®Google Scholar
• Kyriakidis N, López-Cortés A, Vásconez González E, et al. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines. 2021;6(1):28. doi: 10.1038/s41541-021-00292-w
   PubMed Web of Science ®Google Scholar
• Lee K, Malerba F. Catch-up cycles and changes in industrial leadership: Windows of opportunity and responses of firms and countries in the evolution of sectoral systems. Res Policy. 2017;46(2):338–351. doi: 10.1016/j.respol.2016.09.006
   Web of Science ®Google Scholar
• Shin J-S. Dynamic catch-up strategy, capability expansion and changing windows of opportunity in the memory industry. Res Policy. 2017;46:404–416. doi: 10.1016/j.respol.2016.09.009
   Web of Science ®Google Scholar
• Oqubay A, Ohono K, eds. How nations learn. Technological learn, industrial policy, and catch-up. Oxford University Press: (UK); 2019. doi: 10.1093/oso/9780198841760.001.0001
   Google Scholar
• Lee K. Economics of technological leapfrogging. Inclusive and sustainable industrial development working paper series WP 17. Department Of Policy, Research and Statistics. United Nations Industrial Development Organization; 2019. www.unido.org
   Google Scholar
• Malerba F, Lee K. An evolutionary perspective on economic catch-up by latecomers. Ind Corp Change. 2021;30(4):986–1010. doi: 10.1093/icc/dtab008
   Web of Science ®Google Scholar
• Guo L, Zhang M, Dodgson M, et al. Seizing windows of opportunity by using technology-building and market-seeking strategies in tandem: Huawei’s sustained catch-up in the global market. Asia Pac J Manag. 2019;36(3):849–879. doi: 10.1007/s10490-018-9580-1
   Web of Science ®Google Scholar
• Lee K, Lim C. Technological regimes, catching-up and leapfrogging: findings from the Korean Industries. Res Policy. 2001;30(3):459–483. doi: 10.1016/S0048-7333(00)00088-3
   Web of Science ®Google Scholar
• Perez C, Soete L. Catching-up in technology: entry barriers and windows of opportunity. In: Dosi, Editor. Technical change and economic theory. London: Pinter Publishers; 1988.
   Google Scholar
• Perez C. Technological change and opportunities for development as a moving target. CEPAL, Review. 2001;75(75):109–130. doi: 10.18356/20f41c33-en
   Google Scholar
• Morton F. Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry. Int J Ind Organ. 2000;18(7):1085–1104. doi: 10.1016/S0167-7187(98)00057-5
   Web of Science ®Google Scholar
• Islami X, Islami V, Topuzovska Latkovikj M, et al. Barriers hindering the entry of new firms to the competitive market and profitability of incumbents. Manag: J Contemp Manag Issues. 2019;24(2):121–143. doi: 10.30924/mjcmi.24.2.9
   Google Scholar
• Kosi T, Bojnec Š. Institutional barriers to business entry in advanced economies. J Bus Econ Manag. 2013;14(2):317–329. doi: 10.3846/16111699.2011.633348
   Web of Science ®Google Scholar
• Kentikelenis A, Rochford C. Power asymmetries in global governance for health: a conceptual framework for analyzing the political-economic determinants of health inequities. Global Health. 2019;15((Suppl 1):70):1–10. doi: 10.1186/s12992-019-0516-4
   PubMed Web of Science ®Google Scholar
• Feijó Azevedo V, Sandorff E, Siemak B, et al. Potential regulatory and commercial environment for biosimilars in Latin America. Value Health Reg Issues. 2012;1(2):228–234. doi: 10.1016/j.vhri.2012.09.015
   PubMedGoogle Scholar
• Ortiz-Prado E, Ponce-Zea J, Vasconez JE, et al. Current trends for biosimilars in the Latin American market. 2020;9(2):64–74. doi: 10.5639/gabij.2020.0902.011
   Google Scholar
• Schoneveld G. Host country governance and the African land rush: 7 reasons why large-scale farmland investments fail to contribute to sustainable development. Geoforum. 2017;83:119–132. doi: 10.1016/j.geoforum.2016.12.007
   Web of Science ®Google Scholar
• Kruk M, Gage A, Arsenault C, et al. High-quality health systems in the sustainable development goals era: time for a revolution. Lancet Glob Health. 2018;6(11):e1196–252. doi: 10.1016/S2214-109X(18)30386-3
   PubMed Web of Science ®Google Scholar
• Goh W, Wong L. The birth of bio-data science: trends, expectations, and applications. Genomics Proteomics Bioinf. 2021;18(1):5–15. doi: 10.1016/j.gpb.2020.01.002
   Web of Science ®Google Scholar
• Helmy M, Smith D, Selvarajoo K. Systems biology approaches integrated with artificial intelligence for optimized metabolic engineering. Metab Eng Commun. 2020;11:e00149. doi: 10.1016/j.mec.2020.e00149
   PubMedGoogle Scholar
• Xin Y, Man W, Yi Z. The development trend of artificial intelligence in medical: A patentometric analysis. Artif Intell Life Sci. 2021;1:100006. doi: 10.1016/j.ailsci.2021.100006
   Google Scholar
• Liu Z, Roberts R, Lal-Nag M, et al. AI-based language models powering drug discovery and development. Drug Discovery Today. 2021;26(11):2593–2607. doi: 10.1016/j.drudis.2021.06.009
   PubMed Web of Science ®Google Scholar
• Bas TG, Astudillo P, Rojo D, et al. Opinion related to the potential application of Artificial Intelligence (AI) by responsible in charge of logistics and supply chain of medical stock in health centers in North of Chile. Int J Environ Res Public Health. 2023;20(6):x. doi: 10.3390/ijerph20064839
   Google Scholar
• Bas TG, Oliu Castillo C. Biosimilars in developed and developing east and southeast Asian Countries: Japan, South Korea, and Malaysia—Overview, evolution, and regulations assessment. Evol Regulations Assessment Biomed Res Int. 2016;5910403:1–12. PMC4860213 PMID: 27213153. doi: 10.1155/2016/5910403PMCID:
   Google Scholar
• Calvo B, Martinez-Gorostiaga J, Echevarria E. The surge in biosimilars: considerations for effective pharmacovigilance and EU regulation. Ther Adv Drug Saf. 2018;9(10):601–608. doi: 10.1177/2042098618790442
   PubMed Web of Science ®Google Scholar
• Wang A, Xiu X, Liu S, et al. Characteristics of Artificial Intelligence clinical trials in the field of healthcare: a cross-sectional study on ClinicalTrials.Gov. Int J Environ Res Public Health. 2022;19:13691. doi: 10.3390/ijerph192013691
   PubMedGoogle Scholar
• Anurag S, Hemlata Chhabra R, Bhargava A. Approval of biosimilars: a review of unsuccessful regulatory filings. Expert Opin Biol Ther. 2021;21(1):19–28. doi: 10.1080/14712598.2020.1793954
   PubMed Web of Science ®Google Scholar
• Hung A, Vu Q, Mostovoy LA. A systematic review of U.S. biosimilar approvals: what evidence does the FDA require and how are manufacturers responding? J Manag Care Spec Pharm. 2017;23(12):1234–1244. doi: 10.18553/jmcp.2017.23.12.1234
   PubMed Web of Science ®Google Scholar
• Kabir E, Moreino S, Sharif Siam M. The breakthrough of biosimilars: a twist in the narrative of biological therapy. Biomolecules. 2019;9(9):410. doi: 10.3390/biom9090410
   PubMed Web of Science ®Google Scholar
• Chahine B, Ghandour I, Faddoul L. Knowledge and attitude of community pharmacists toward biosimilar medicines: A cross-sectional study in Lebanon. Clin Epidemiol Global Health. 2023;21:101287. doi: 10.1016/j.cegh.2023.101287
   Web of Science ®Google Scholar
• Drelichman G, Castañeda-Hernández G, Ar M, et al. The road to biosimilars in rare diseases - ongoing lessons from Gaucher disease. Am J Hematol. 2020;95:233–237. doi: 10.1002/ajh.25701
   PubMed Web of Science ®Google Scholar
• Jung EH, Sarpatwari A, Kesselheim AS, et al. FDA and EMA biosimilar approvals. J Gen Intern Med. 2020;35:1908–1910. doi: 10.1007/s11606-019-05408-6
   PubMed Web of Science ®Google Scholar
• Niazi SK. Biosimilars: Harmonizing the Approval Guidelines. Biologics. 2022;2(3):171–195. doi: 10.3390/biologics2030014
   Google Scholar
• Koyfman H. Biosimilarity and interchangeability in the biologics price competition and innovation act of 2009 and FDA’s 2012 draft guidance for industry. Biotechnology Law Report. 2013;238:4. doi: 10.1089/blr.2013.9884
   Google Scholar
• Koballa K. The biologics price competition and innovation act: is a generic market for biologics attainable? 9 Wm. & Mary Bus. L Rev. 2018; 479. https://scholarship.law.wm.edu/wmblr/vol9/iss2/8
   Google Scholar
• Heled Y. The biologics price competition and innovation Act 10–A stocktaking. Tex A&M J Prop L. 2021;7(1):81. doi: 10.37419/JPL.V7.I1.3
   Google Scholar
• Chen Y, Lehmann A, Santos da Silva J What’s next for biosimilars in emerging markets? [cited 2022 Mar 13]. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/whats-next-for-biosimilars-in-emerging-markets
   Google Scholar
• Wouters O, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323(9):844–853. doi: 10.1001/jama.2020.1166
   PubMed Web of Science ®Google Scholar
• Simoens S, Huys I. R&D costs of new medicines: a landscape analysis. Front Med. 2021;8:760762. doi: 10.3389/fmed.2021.760762
   Web of Science ®Google Scholar
• Salerno M, Matsumoto C, Ferraz I. Biofármacos no Brasil: Características, Importância e Delineamento de Políticas Públicas para seu Desenvolvimento. Brazil: Instituto de Pesquisa Econômica Aplicada – ipea. 2398; 2018.
   Google Scholar
• https://progenericos.org.br/biossimilares/
   Google Scholar
• ASCOM. 2018. Primeiro medicamento biológico por comparabilidade é registrado pela Anvisa. 2015. Disponível em: [cited 2023 Mar 18]. Available from: http://portal.anvisa.gov.br/noticias.p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_col_id=column2&p_p_col_pos=1&p_p_col_count=2&_101_INSTANCE_FXrpx9qY7FbU_groupId=219201&_101_INSTANCE_FXrpx9qY7FbU_urlTitle=primeiro-medicamento-biologico-por-comparabilidade-e-registrado-pela-anvisa&_101_INSTANCE_FXrpx9qY7FbU_struts_action=%2Fasset_publisher%2Fview_content&_101_INSTANCE_FXrpx9qY7FbU_assetEntryId=219797&_101_INSTANCE_FXrpx9qY7FbU_type=content
   Google Scholar
• Karp P, Gatto M, Batto M, et al. Biosimilar monoclonal antibodies in Latin America. In: Feijó Azevedo V Moots R, editors. Biosimilars. 2021. doi: 10.5772/intechopen.101227
   Google Scholar
• https://drug-dev.com
   Google Scholar
• Defossez D. Global regulation of international intellectual property through agreement on trade-related aspects of intellectual property rights (TRIPS): The European Union and Brazil. Journal Of Law And Regulation, [SL]. 2017;3(2):131–160.
   Google Scholar
• Chimpango B. Vaccine nationalism and equitable access to COVID-19 pharmaceuticals: TRIPS Agreement under trial (again). J Int Trade Law Policy. 2021;20(3):166–183. doi: 10.1108/JITLP-03-2021-0012
   Web of Science ®Google Scholar
• Gamba S. The effect of intellectual property rights on domestic innovation in the pharmaceutical sector. World Dev. 2017;99:15–27.
   Web of Science ®Google Scholar
• Tenni B, Moir H, Townsend B, et al. What is the impact of intellectual property rules on access to medicines? A systematic review. Globalization Health. 2022;18(1):18–40. doi: 10.1186/s12992-022-00826-4
   PubMed Web of Science ®Google Scholar
• [cited 2023 Jun 25]. Available from: https://www.fiercepharma.com/special-report/top-15-blockbuster-patent-expirations-coming-decade
   Google Scholar
• [cited 2023 Jun 25]. Available from: https://www.fiercepharma.com/special-reports/top-10-drugs-losing-us-exclusivity-2022
   Google Scholar
• [cited 2023 Jun 25]. Available from: https://www.fiercepharma.com/special-report/top-10-drugs-losing-u-s-exclusivity-2021
   Google Scholar
• Niazi SK. The coming of age of biosimilars: a personal perspective. Biologics. 2022;2:107–127. doi: 10.3390/biologics2020009
   Google Scholar
• Fontanillo M, Körs B, Monnard A Three imperatives for R&D in biosimilars 2022. cited 2022 Mar 13 Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/three-imperatives-for-r-and-d-in-biosimilars#/
   Google Scholar
• Teran E, Gomez H, Hannois D, et al. Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective. Lancet Oncol. 2022;23(7):e348–58. doi: 10.1016/S1470-2045(22)00121-8
   PubMed Web of Science ®Google Scholar
• Xibille D, Carrillo S, Huerta-Sil G, et al. Current state of biosimilars in Mexico: the position of the Mexican College of Rheumatology, 2016. Reumatol Clin. 2018;14(3):127–136. doi: 10.1016/j.reuma.2017.07.002
   PubMed Web of Science ®Google Scholar
• http://antigo.anvisa.gov.br
   Google Scholar
• Ramírez-Telles M, Mora-Román J, Fallas-Cartín M. Registro sanitario de medicamentos biológicos y biotecnológicos en América Latina. Marketing authorization of biologic and biotechnological products in Latin America. Ars Pharm. 2021;62(2):131–143. doi: 10.30827/ars.v62i2.15862
   Google Scholar
• Ozcagli E, Alpertunga B, Tsatsakis AM. Biosimilar Drugs and Pharmacovigilance. Pharm Anal Acta. 2015;6(9):416. doi: 10.4172/21532435.1000416
   Google Scholar
• Sardella M, Belcher G, Lungu C. Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance. Ther Adv Drug Saf. 2021;12: doi: 10.1177/20420986211038436
   PubMed Web of Science ®Google Scholar
• Bas TG, Oliu CA. Innovation strategy management survey of the Chilean biomedical industry. Assessment of windows of opportunities to reduce technological Gaps. Int J Health Plann Manage. 2018;33(2):E512–E530. doi: 10.1002/hpm.2501
   PubMed Web of Science ®Google Scholar
• Tunyi A, Ntim C. Location advantages, governance quality, stock market development and firm characteristics as antecedents of African M&As. J Int Manag. 2016;22:147–167. doi: 10.1016/j.intman.2016.01.005
   Web of Science ®Google Scholar
• Khodary Y. Good governance: A new perspective for institutional reform—a comparative view of water, education and health institutions in Egypt. Int J Public Policy. 2016;12(3/4/5/6):359–377. doi: 10.1504/IJPP.2016.079747
   Google Scholar
• de Assis MR, Pinto V. Strengths and weaknesses of the Brazilian regulation on biosimilars: A critical view of the regulatory requirements for biosimilars in Brazil. Ther Adv Musculoskelet Dis. 2018;10(12):253–259. doi: 10.1177/1759720X18809683
   PubMed Web of Science ®Google Scholar
• Aljarallah R. Natural resource dependency, institutional quality and human capital development in gulf countries. Heliyon. 2020;6(7):e04290. doi: 10.1016/j.heliyon.2020.e04290
   PubMed Web of Science ®Google Scholar
• Ledón N, Lage A Biosimilars and the Real World. MEDICC Review 2017;19, (4):9–14.
   PubMed Web of Science ®Google Scholar
• Iqbal Z, Sadaf S. Biosimilars: A comparative study of regulatory, safety and pharmacovigilance monograph in the developed and developing economies. J Pharm Pharm Sci. (Www.Cspscanada.org) 2022;25:149–182. doi: 10.18433/jpps32433
   PubMed Web of Science ®Google Scholar
• Kirchhoff CF, Wang XZ, Conlon HD, et al. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696–2705. doi: 10.1002/bit.26438
   PubMed Web of Science ®Google Scholar
• Ibarra-Cabrera R, Carolina Mena-Pérez S, Bondani-Guasti A, et al. Review on the worldwide regulatory framework for biosimilars focusing on the Mexican case as an emerging market in Latin America. Biotechnol Adv. 2013;31(8):1333–1343. doi: 10.1016/j.biotechadv.2013.05.005
   PubMed Web of Science ®Google Scholar
• Mayoral-Zavala A, Esquivel-Aguilar A, Del Real-Calzada C-M. Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico. Revista de Gastroenterología de México. 2018;83(4):414–423. doi: 10.1016/j.rgmx.2018.03.003
   Web of Science ®Google Scholar
• Chen W, Liu X, Zhang S, et al. Artificial intelligence for drug discovery: Resources, methods, and applications. Mol Ther Nucl Acids. 2023;31:691–702. doi: 10.1016/j.omtn.2023.02.019
   Google Scholar
• Mann M, Kumar C, Zeng WF, et al. Artificial intelligence for proteomics and biomarker discovery. Cell Syst. 2021;12(8):759–770. doi: 10.1016/j.cels.2021.06.006
   PubMed Web of Science ®Google Scholar
• Bhattamisra SK, Banerjee P, Gupta P, et al. Artificial Intelligence in pharmaceutical and healthcare research. Big Data Cogn Comput. 2023;7(1):10. doi: 10.3390/bdcc7010010
   Google Scholar